Guest post Medicine Research integrity

Anil Sood and how much MD Anderson doesn’t care: whistleblowers speak out

"The graduate school at University of Texas MD Anderson does not care and keep sending students to his lab, Sood is a member of faculty there. RIO at MDACC doesn't care because witnesses either left the country or are too afraid to speak."

My earlier article presented the worrisome research integrity record at the gigantic US cancer research hospital MD Anderson Cancer Center, part of the University of Texas in Houston. Its particular focus was the ovarian cancer researcher Anil Sood, professor of Gynecologic Oncology and Reproductive Medicine and co-director of Center for RNA Interference and Non-Coding RNAs at MD Anderson. Meanwhile I have been contacted by no less than 4 former Sood associates with their concerns, because they say MD Anderson does not take them seriously. A pseudonymous guest post by one of these whistleblowers, together with some evidence, is published below.

Sood’s record of appalling duplications of microscopy image and western blot bands in his papers is evident on PubPeer, no less than 40 papers are flagged, spanning so far a period from 2004 until now. The whistleblowers who contacted me now also accuse Sood of inappropriate data handling, since he was apparently removing or adjusting data points on a whim, and taught his lab members to do the same. The results based on this creatively acquired mouse experiment data as well as duplicated images served to initiate at MD Anderson a clinical trial with up to 90 “patients with histologic proof of advanced solid tumors ” to test a siRNA based therapy, this trial is lead by Sood’s associate Robert Coleman, who is professor at the same department.

Worst of all: MD Anderson doesn’t care about what happens in Sood’s lab. They do have guidelines for research integrity, printable as pdf, but those seem to serve as a kind of toilet paper to wipe professorial bums with. As a whistleblower informed me, nine researchers working on different projects in Sood’s lab complained to Office of Research Integrity (ORI) or MD Anderson’s own Research Integrity Officer (RIO) William Plunkett or Department Chairs or Ombuds Office or Dean of Graduate School, Michelle Barton, since August 2016. In fact, those who complained where told to find another job, or were dealt otherwise with. There never was any investigation, only “leak of confidentiality”, while the University of Texas graduate school keeps sending fresh students to learn at Sood’s lab. Meanwhile, as a whistleblower wrote: “Most Sood core members already escaped, and got a job thanks to their publication with suspected allegations“.

An example of a Sood western blot with an apparent gel band duplciation, on PubPeer. Such data serves as template for a clinical trial with up to 90 desperate cancer patients.

My previous attempt to contact Plunkett led nowhere. He simply sent me what was supposed to be an out-of-office message, without indicating when he might be returning to answer my concerns. I never heard from him since, hardly surprising. This was what he ignored so far, according to a whistleblower, a total nine reports since August of 2016:

  • “One lab member, who also went to PubPeerMangala et al, JCI Insight 2016; Fig 3E. Sood ignored one of honest authors’ concerns regarding all tumors being in the brains of mice who displayed abnormal behaviors, also the picture of brain was cropped. This issue has been reported to RIO and Chair of Gynecologic Oncology and Reproductive Medicine with solid evidence but no any update from them.


  • Two lab members reported to RIO and deans of graduate school (Michelle Barton) about Sood’s research misconduct for his manipulation of in vivo experiment.


  • Another two lab members reported to the chairs of Gynecologic Oncology department with their concerns.


  • Another four more lab members reported to RIO and ORI with Sood’s research misconduct in vivo work”.


  • Nothing happened, no-one seems to care at MD Anderson Cancer Center (MDACC). So here is another whistleblower report, by a pseudonymous Hydrangea quercifolia, including the evidence this hydrangea plant forwarded to me.  It primarily concerns the recent Sood lab paper Nagaraja et al, JCI Insight 2017, some of the date meanwhile found its way to PubPeer.
kubrick-science-4-001.jpg

Anil Sood and how much MD Anderson doesn’t care

By Hydrangea quercifolia

The graduate school at University of Texas MD Anderson does not care and keep sending students to his lab, Sood is a member of faculty there. RIO at MDACC doesn’t care because witnesses either left the country or are too afraid to speak.

These are the photographs of original documentation from in vivo experiment that was recently published by Anil Sood and coworkers in JCI Insight. Archana S Nagaraja was the first author and a graduate student from Sood’s lab. These notes have the original hand writing of Anil Sood – Mouse weight, tumor weight, location of metastasis, number of metastasis. Archana wrote numbers of OCT and paraffin [tissue embedding material, for purpose of sectioning, -LS] blocks. The control group from this experiment was shared with another experiment –  siSnail RNA for Dr. Steve Cole.

As you can see on Fig 5D, titled “INHBA silencing in HEYA8 model” in Archana’s paper, numbers of tumor weight and tumor nodules do not match with what was recorded during the take down on the protocol. All outliers were removed.

sood 2017
Data calculated from the original records doesn’t match what Sood published. Click to download the spreadsheet and ANOVA statistics.

Robert Dood, the second author on that paper, performed that experiment. I will now describe what happened after the in vivo experiment, there are also audio recordings for that. Lab members were discussing how Sood manipulated tumor weight and tumor nodules during Robert’s experiment. Lingegowda Mangala, the most senior lab member admitted on that recording that Sood always does it. He participates in every take-down and to record false numbers by himself. The trick is he wants to know the treatment groups in advance so he can adjust those numbers according to his expectations and hypothesis. People are dissecting the tumors in good faith, call out the numbers of nodules and pattern of metastasis, but Sood then records false numbers, and then measures and records false tumor weights by himself.

All lab members knew about that for years. In Fall 2016, several postdocs reported that to William Plunket at the ROI, but they were then told to find another job. American medical fellows who were participating in Robert’s study, and are heard on the recording, were too scared to report that to ROI.  MD Anderson never contacted them and let them go without a word, although ROI received a list of witnesses from Robert’s take down. Medical fellows manipulated most of the experimental data in the past. Sood helped them generate beautiful in vivo data, and all of them became successful physicians and investigators. Sood was educator of the year, for several years in a row. This is a true synergy.

This is how tumors from in vivo experiments are collected:

At the end of each in vivo experiment, Dr. Anil Sood and a group of selected lab members dissect ovarian tumor mass from abdominal cavity of experimental mice. Treatment groups are blinded to all lab members during the take-down to avoid bias, but treatments are always unmasked to Dr. Anil Sood, per his request. Lab members harvesting tumors from mice need to count the number of dissected tumor nodules and assess the location of metastases. Tumor samples are then placed on weight papers and are given to Dr. Sood, who weights the tumor samples on the scale. Next, lab members call their findings and Dr. Sood records numbers of tumor nodules, tumor weight and pattern of metastases on the study protocol by hand using a pen or a pencil. The study leader does not participate in the tumor dissection and loads tumor samples into tubes for freezing. Many medical fellows and other international lab visitors noticed discrepancies in what was recorded in study protocols by Dr. Sood as opposed to what was called out by them during the take-down. Some members even decided to record the conduct of their in vivo experiments, take pictures of study protocols, and to clear up their doubts. There is an original audio recording documenting such a session.

Recently, some materials were given to ROI at MDACC and findings were reported to Graduate School at UT MDACC. A female senior lab member captured on another audio recording admits that Dr. Sood always participates in collaborative projects whenever in vivo mouse models of cancer are utilized. ROI at MDACC doesn’t seem to see any implications though.

It seems that all evidence is being consistently marginalized and allegations are dismissed. Current and former lab members are suffering because they have to tolerate this situation. They are too afraid to testify since all medical fellows and PhDs depend so helplessly on Sood’s recommendations. Since most of the eye-witnesses have already left MDACC, or even returned to their home countries, the investigation will most likely be buried. But should collaborators care about their research? What would happen if any of that questionable data was used to design and rationalize the conduct of clinical trials?

The sad thing is that Sood generated preclinical data on Ephrin siRNA on mice, and now that siRNA is in phase 1 clinical trial. The preclinical in vivo data on EphA1 in ovarian and endometrial cancer from Dr. Sood most likely gave a rationale to phase 1 clinical trial NCT01591356 on siRNA-EphA2-DOPC that is sponsored by and currently ongoing in M.D. Anderson Cancer Center. Coincidentally, this trial is led by Dr.  Robert Coleman, a friend and long-term collaborator of Dr. Anil Sood, and tumor samples and biofluids from human subjects are analyzed by Dr. Sherry Wu, a former postdoc and a current assistant professor under supervision of Dr. Anil Sood. Apparently, there is no reason to believe that there is something wrong with the conduct of the trial and the quality of that data. However, the quality of preliminary experimental data on EphA2 from the Sood’s group is not that apparent any more.  Several publications on EphA2 in ovarian and endometrial cancer from Sood lab are already being questioned, as reported in PubPeer.

  1. https://pubpeer.com/publications/040E8DB1C9C99239AB96CB3C21C44C
  2. https://pubpeer.com/publications/DC2711EB12252C11260090ABD6A2E1
  3. https://pubpeer.com/publications/FF8EB6BE7BC568814DCDDBFA7A8F02

Thankfully, cancer patients do not need to care about “hot stories” on mechanisms of drug action. Unexplained irregularities and duplication in presented Western blot panels, and inadvertently cropped and duplicated IHC microphotograph neither compromise patients’ safety or impact the efficacy of siRNA-EphA2-DOPC used in the clinical trial. Let us hope that this clinical trial will make cancer history by bringing a cure and relief to ovarian cancer patients, and national recognition to its co-founders.

In any case, working with and loyalty to Dr. Sood is a really good investment in your career. Medical fellows who completed their fellowships under supervision of Dr. Sood published their research in high-tier journals and found respectful jobs. Their work is now being questioned also, as noted in PubPeer.

Anil K. Sood, MD – his beginning, perhaps his fellowship

Aparna A. Kamat, MD

Alpa Nick, MD, MS

Charles N. Landen, MD

Chunhua Lu, MD

Premal H Thaker, MD

Rebecca A Previs, MD



One-Time
Monthly

I thank all my donors for supporting my journalism. You can be one of them!
Make a one-time donation:

I thank all my donors for supporting my journalism. You can be one of them!
Make a monthly donation:

Choose an amount

€5.00
€10.00
€20.00
€5.00
€10.00
€20.00

Or enter a custom amount


Your contribution is appreciated.

Your contribution is appreciated.

DonateDonate monthly

22 comments on “Anil Sood and how much MD Anderson doesn’t care: whistleblowers speak out

  1. There is a mass of problematic data. The Texas University system is ultimately responsible for MD Anderson.

    Like

  2. I sent a report to the chancellor at UT in some months ago describing a number of apparently problematic issues, but didn’t hear anything back. Not even a confirmation of receipt!

    I am really disappointed, especially since we are talking about cliniical trials and that they may have been based on erroneous research data. Why doesn’t an academic institution like MD Anderson apparently don’t bother?! The same is true for the different patient organizations like AACR. They supposed to care about the cancer patients, and say so when collecting money, but when they hardly correct the published literature they show something else.

    Just look at all the B. Aggarwal papers out there that still are not retracted. The articles are more art than science. It is a scandal of dimensions!

    Like

  3. I hope new president, Dr. Peter Pisters will take this issue very seriously at MDACC.
    https://www.utsystem.edu/news/2017/09/18/peter-pisters-officially-named-president-ut-md-anderson

    Like

  4. Res Integrity

    Sorry! Leonid, Nothing will be happened whatever whistleblowers is trying to change the world, at least at MDACC.
    You may get a hint from comments in this link;
    http://retractionwatch.com/2012/01/31/md-anderson-investigating-researcher-bharat-aggarwal-over-images/

    Like

  5. Pingback: Collages by Paul Workman, from the Golden Age of Biological Imaging – For Better Science

  6. Pingback: Princess Sabine, her Ombudsman chaperone and a frog – For Better Science

  7. Anonymous

    It looks like this group has been started to correct questionable figures
    https://pubpeer.com/publications/01F6312A596D6D2D855C00B2099ADF

    Like

  8. Clin Cancer Res. 2002 Sep;8(9):2924-32.
    The paradoxical expression of maspin in ovarian carcinoma.
    Anil K. Sood, Mavis S. Fletcher, Lynn M. Gruman, Jeremy E. Coffin, Sarvenaz Jabbari, Zhila Khalkhali-Ellis, Nancy Arbour, Elisabeth A. Seftor and Mary J. C. Hendrix
    Author information

    1
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242-1109, USA. anil-sood@uiowa.edu

    Figure 1D. See: https://pubpeer.com/publications/647C421BFFDD1A17C2583516AF5075

    Like

  9. Question

    39 papers with problematic figures have been come out from this group;
    https://forbetterscience.com/2017/07/17/anil-sood-and-other-questionable-stars-of-md-anderson/

    Like

  10. Fernando Pessoa

    2018 Anil Sood correction.

    Cancer Res. 2016 Dec 15;76(24):7194-7207. Epub 2016 Oct 14.
    Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
    Kanlikilicer P1,2, Rashed MH1,3, Bayraktar R1, Mitra R2,4, Ivan C1,2, Aslan B1,2, Zhang X2,4, Filant J4, Silva AM1, Rodriguez-Aguayo C1,2, Bayraktar E1, Pichler M1,5, Ozpolat B1,2, Calin GA1,2,6, Sood AK2,4,6, Lopez-Berestein G7,2,6.
    Author information

    1 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
    2 Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas.
    3 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
    4 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
    5 Division of Oncology, Medical University of Graz, Austria.
    6 Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
    7 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. glopez@mdanderson.com.

    2018 correction notice.
    http://cancerres.aacrjournals.org/content/78/12/3402

    In the original version of this article (1), the same β-actin bands appear in multiple places in Figs. 3C, 4E, and 5B, with no explanation for the duplicated images. The authors state that the proteins were all probed on the same membrane, and thus, the same β-actin images were used in the figures in question. The legends of Figs. 4E and 5B have been corrected to reflect this in the online HTML and PDF versions of the article. The authors regret this omission.
    ©2018 American Association for Cancer Research.

    Reference
    1.↵Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, et al. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res 2016;76:7194–207.

    Pubpeer record: https://pubpeer.com/publications/46B54DFF7ED1EE2FCC0AEB59310163

    Like

  11. Pingback: Scratchy cancer cure discoveries of Ruben Plentz – For Better Science

  12. Pingback: Gradito al regime - Ocasapiens - Blog - Repubblica.it

  13. Pingback: New ERC President Mauro Ferrari was partner of Texas cheater Anil Sood – For Better Science

  14. Pingback: Nasty Jasti Rao, or what’s wrong with US biomedicine – For Better Science

  15. Pingback: The wizard men curing breast cancer – For Better Science

  16. Pingback: Amato Giaccia: too big to fall – For Better Science

  17. Zebedee

    2020 retraction for anil Sood and others:

    Nature . 2014 Aug 28;512(7515):431-5. doi: 10.1038/nature13375. Epub 2014 Jun 25.
    miR-34a Blocks Osteoporosis and Bone Metastasis by Inhibiting Osteoclastogenesis and Tgif2
    Jing Y Krzeszinski 1, Wei Wei 1, HoangDinh Huynh 1, Zixue Jin 1, Xunde Wang 1, Tsung-Cheng Chang 2, Xian-Jin Xie 3, Lin He 4, Lingegowda S Mangala 5, Gabriel Lopez-Berestein 6, Anil K Sood 7, Joshua T Mendell 8, Yihong Wan 9

    Affiliations
    1Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
    2Department of Molecular Biology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
    31] Simmons Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA [2] Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
    4Division of Cellular and Developmental Biology, Molecular and Cell Biology Department, University of California at Berkeley, Berkeley, California 94705, USA.
    51] Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
    61] Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
    71] Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [3] Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
    81] Department of Molecular Biology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA [2] Simmons Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
    91] Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA [2] Simmons Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

    https://www.nature.com/articles/s41586-020-2273-1

    “Upon re-examination of the bone histomorphometry data in Extended Data Figs. 1i, 2d, 3h, 4h, 5n, 6e, 9g and 10f of this Letter, anomalies were found that call into question the integrity of these data. These concerns undermine the confidence in the study and the authors thus wish to retract the Letter in its entirety. The authors regret this situation and apologize to the scientific community. All authors agree with the Retraction, but author Xunde Wang did not respond.”

    https://retractionwatch.com/2020/06/01/nature-retracts-study-touted-as-step-toward-treatments-for-bone-diseases/

    Like

  18. Pingback: Xiongbin Lu nanobombs cancer with fluorescent nude mouse recycling – For Better Science

  19. Anil Sood in 2022, or how “big journals” don’t care about his cheating history.https://pubpeer.com/publications/527470C5B9A8C5C68DD6639B12DA7A#2
    Outrageous how such a fraud keeps getting money and worse, he is even leading the ovarian cancer “moonshot program”.

    Like

Leave a comment